Dublin, Aug. 22, 2023 (GLOBE NEWSWIRE) -- The "Global Allogeneic Cell Therapy Market: Distribution by Type of Cell Therapy, Source of Cell, Target Indication, Therapeutic Area and Key Geographical Regions, 2023-2035" report has been added to ResearchAndMarkets.com's offering.
The global allogeneic cell therapy market is projected to witness significant growth in the coming years, with an estimated worth of USD 0.9 billion in 2023, projected to grow at a compounded annual growth rate (CAGR) of 14% during the forecast period from 2023 to 2035.
The field of regenerative medicine has witnessed a significant evolution with the emergence of cell therapies. Among these, allogeneic cell therapy has gained substantial attention and is projected to drive transformative changes in the healthcare industry. Allogeneic cell therapies, also known as "off-the-shelf" therapies, have the potential to revolutionize treatment paradigms due to their immediate accessibility, scalability, and cost-effectiveness. In this comprehensive overview, we delve into the key drivers, trends, challenges, and growth prospects of the global allogeneic cell therapy market.
Allogeneic vs. Autologous Cell Therapy: Approaches and Advantages
Allogeneic and autologous cell therapies are two distinct approaches in the realm of regenerative medicine. Autologous therapies involve harvesting a patient's own cells, processing them ex-vivo, and then reintroducing them back into the same patient. While this approach ensures compatibility and minimizes the risk of immune rejection, it requires a longer production timeline, as each patient's cells need to be processed individually. On the other hand, allogeneic cell therapies utilize cells from a healthy donor, which can be administered directly to a genetically similar patient or stored in a cell bank for future use.
The key advantage of allogeneic cell therapy lies in its off-the-shelf availability, eliminating the need for individualized production for each patient. Allogeneic therapies offer consistent product quality due to rigorous quality control measures during processing. Additionally, centralized manufacturing processes result in reduced costs. The flexibility to approach the same donor or choose a different donor for subsequent treatments enhances the appeal of allogeneic cell therapies.
Pipeline and Clinical Trials: A Landscape of Innovation
The allogeneic cell therapy market is witnessing rapid innovation, with numerous stakeholders engaged in developing a diverse range of therapies for various indications. Currently, over 470 allogeneic cell therapies are being evaluated in different stages of preclinical and clinical development. These therapies target a wide spectrum of disorders, including infectious diseases, neurological disorders, oncological disorders, and more.
Gamida Cell's recent FDA approval of its umbilical cord blood-derived allogeneic stem cell therapy, Omisirge (omidubicel-onlv), for the treatment of hematologic malignancies highlights the market's progress. The continuous efforts of both industry and non-industry players, combined with encouraging clinical trial results, are contributing to the growing momentum in the allogeneic cell therapy landscape.
Partnerships and Collaborations: Driving Innovation Forward
Collaboration has emerged as a pivotal trend in the allogeneic cell therapy market. Industry players are forming strategic alliances with both industry and non-industry partners to accelerate research, development, and commercialization efforts. Notably, over 90 partnerships have been established since 2019, spanning areas such as research and development, product and technology licensing, and novel therapy development.
These collaborations facilitate knowledge exchange, resource sharing, and access to complementary expertise, thereby expediting the development of innovative allogeneic cell therapies. For instance, Tessa Therapeutics' partnership with the US National Cancer Institute for the development of allogeneic CD30.CAR-modified Epstein-Barr virus-specific T-cell therapy exemplifies the potential of collaborative efforts.
Investment and Funding: Fueling Growth and Innovation
Investor interest in the allogeneic cell therapy market has been robust, as evidenced by the substantial funds raised by companies engaged in developing these therapies. Over the past four years, approximately USD 8.8 billion has been invested globally. Venture rounds have contributed significantly to funding, reflecting the growing confidence in the market's potential.
Legend Biotech's initial public offering (IPO), which raised USD 487.3 million, showcases the market's attractiveness to investors. Funding is not only driving the development of allogeneic cell therapies but also fostering innovation and technology advancement in this space.
Market Growth Factors: Challenges and Opportunities
Several factors are driving the growth of the allogeneic cell therapy market. The ongoing efforts of both industry and non-industry players, coupled with rising prevalence of chronic diseases and non-malignant disorders, are fostering the development and adoption of allogeneic therapies. Moreover, the challenges associated with producing autologous cell therapies, which are personalized and time-consuming, further underscore the potential of allogeneic therapies to revolutionize healthcare delivery.
Clinical Trials: Investigating Efficacy and Safety
The burgeoning allogeneic cell therapy landscape is supported by a multitude of clinical trials evaluating the efficacy and safety of these therapies. More than 365 clinical trials are currently registered, targeting various indications such as hematologic malignancies, solid tumors, infectious diseases, and neurological disorders. Geographically, North America hosts the majority of these trials, accounting for around 55% of the total enrollment.
Among the noteworthy trials, the allogeneic CAR T cell therapy ALLO-715 (developed by Allogene) has demonstrated promising results in Phase I clinical trials for the treatment of relapsed/refractory multiple myeloma, further validating the potential of allogeneic cell therapies.
Regional Market Share: North America's Dominance
North America is anticipated to capture over 60% of the global allogeneic cell therapy market share by 2035. The region boasts a thriving ecosystem of companies focused on developing allogeneic cell therapies. Additionally, rising disease incidence, FDA approvals, and government support for reimbursement are driving the market's growth in North America. Government initiatives that provide reimbursement for expensive allogeneic cell therapies underscore the region's recognition of the transformative potential of these therapies in improving patient outcomes.
Key Players and Future Prospects
Numerous key players are actively engaged in the development of allogeneic cell therapies, targeting a diverse range of indications. These players include Artiva Biotherapeutics, Allogene Therapeutics, Atara Biotherapeutics, Celularity, CRISPR Therapeutics, Fate Therapeutics, Mesoblast, Poseida Therapeutics, and more. The industry's dynamism and innovation, coupled with increasing approvals and advancements in cell therapy manufacturing, are poised to drive substantial growth in the allogeneic cell therapy market during the forecast period.
Conclusion
The global allogeneic cell therapy market is witnessing remarkable progress, fueled by innovative approaches, strategic collaborations, substantial investments, and encouraging clinical trial outcomes. Allogeneic cell therapies hold the promise of transforming healthcare delivery by offering immediate availability, scalability, and cost-effectiveness. As industry and non-industry players continue to push the boundaries of innovation, the allogeneic cell therapy market is poised for substantial growth, paving the way for a new era in regenerative medicine.
Key Topics Covered
1. PREFACE
1.1. Allogeneic Cell Therapy Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Overview of Allogeneic Cell Therapy
3.2. Manufacturing Process of Allogeneic Cell Therapy
3.3. Advantages Offered by Allogeneic Cell Therapy
3.4. Challenges Associated with Allogeneic Cell Therapy
3.5. Recent Developments in Allogeneic Cell Therapy Industry
3.6. Future Perspectives
4. MARKET LANDSCAPE
4.1. Allogeneic Cell Therapies: Market Landscape
4.2. Allogeneic Cell Therapies: Developer Landscape
5. PARTNERSHIPS AND COLLABORATIONS
5.1. Chapter Overview
5.2. Partnership Models
5.2. Allogeneic Cell Therapies: Partnerships and Collaborations
6. FUNDING AND INVESTMENTS
6.1. Chapter Overview
6.2. Types of Funding
6.3. Allogeneic Cell Therapies: Funding and Investments
7. CLINICAL TRIAL ANALYSIS
7.1. Analysis Methodology and Key Parameters
7.2. Allogeneic Cell Therapies: Clinical Trial Analysis
8. KEY OPINION LEADERS
8.1. Methodology and Key Parameters
8.2. Allogeneic Cell Therapies: Key Opinion Leaders (KOLs)
9. MARKET FORECAST AND OPPORTUNITY ANALYSIS
9.1. Chapter Overview
9.2. Forecast Methodology and Key Assumptions
9.3. Global Allogeneic Cell Therapy Market, 2023-2035
9.4. Allogeneic Cell Therapy Market: Product-wise Sales Forecast, 2023-2035
10. EXECUTIVE INSIGHTS
10.1. Chapter Overview
10.2. Mesoblast
10.3. Triumvira Immunologics
11. APPENDIX I: TABULATED DATA
12. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
Companies Mentioned (378 Total)
- 920th Hospital of Joint Logistics Support Force
- AbbVie
- Academisch Medisch Centrum
- Acepodia
- Adaptimmune Therapeutics
- Adicet Bio
- Aegle Therapeutics
- Affiliated Hospital to Academy of Military Medical Sciences
- Affimed
- Alaunos Therapeutics
- Allogene Therapeutics
- AlloVir
- Alpha Biopharma
- Altaco XXI
- Amgen
- Angiocrine Bioscience
- Anhui Provincial Hospital
- Ann & Robert H. Lurie Children's Hospital of Chicago
- Anterogen
- Antion Biosciences
- APICES
- Athersys
- Artiva Biotherapeutics
- Astellas Pharma
- Atara Biotherapeutics
- Athenex
- Athersys
- Autolomous
- Azidus Brasil
- Bayer
- Baylor College of Medicine
- Baylx
- Be The Match BioTherapies
- Beijing 302 Hospital
- Beijing Doing Biomedical
- Beijing GD Initiative Cell Therapy Technology
- Beijing Immunochina Medical Science & Technology
- JD Biotech
- Beijing SH biotechnology
- Beth Israel Deaconess Medical Center
- BHI Therapeutic Sciences
- BioCardia
- Bioceltech Therapeutics
- BioCentriq
- Biomedical Advanced Research and Development Authority (BARDA)
- Biorasi
- Bioray Laboratories
- BioSenic (Previously known as Bone Therapeutics)
- Bristol Myers Squibb
- California Institute for Regenerative Medicine
- Cancer Research UK
- Capricor Therapeutics
- CardioCell
- Caribou Biosciences
- Cartesian Therapeutics
- Junta de Castilla y Leon
- Catalent Pharma Solutions
- Catamaran Bio
- Cedars-Sinai Medical Center
- Celixir
- Cell2Cure
- Cellavita
- Cell and Gene Therapy Catapult
- Cellectis
- Cellenkos
- Cellerant Therapeutics
- Cellerix
- Celltex Therapeutics
- Cellular Biomedicine Group (CBMG)
- Celularity
- Celyad Oncology
- Center for Breakthrough Medicines
- Central South University
- Centre Hospitalier Universitaire de Limoges
- Chabiotech
- Chandler Regional Medical Center
- Changhai Hospital
- Huaxia Intech (Biotech) Biotechnology (Previously known as China Immunotech Biotechnology)
- China-Japan Friendship Hospital
- Chinese Academy of Medical Sciences
- Chinese PLA General Hospital
- Cipla
- Citospin
- Cleveland Clinic
- Cliniques universitaires Saint-Luc
- CoImmune
- Copenhagen University Hospital
- Corestem
- CRISPR Therapeutics
- Cynata Therapeutics
- CytoMed Therapeutics
- Cytopeutics
- Cytora
- Cytovia Therapeutics
- Daewoong Pharmaceutical
- Department of Health and Human Services
- Deverra Therapeutics
- Direct Biologics
- DiscGenics
- Dt&SanoMedics
- Duke University
- EdiGene
- Editas Medicine
- ElevateBio
- ENCell
- Enlivex Therapeutics
- European Commission
- European Union
- Ever Supreme Bio Technology
- Fate Therapeutics
- Ferrer Internacional
- FGK Clinical Research
- FibroBiologics
- Fondazione Matilde Tettamanti Menotti De Marchi Onlus
- Formula Pharmaceuticals
- Fortress Biotech
- Fred Hutchinson Cancer Center
- Fresno Community Hospital and Medical Center
- FUJIFILM Diosynth Biotechnologies
- Fundamenta Therapeutics
- Gamida Cell
- GC Cell
- Gemeinsamer Bundesausschuss
- Genentech
- GentiBio
- Genzyme
- Ghent University
- Global Cord Blood Corporation
- Glycostem Therapeutics
- Gracell Biotechnologies
- Granzer Regulatory Consulting & Services
- Greenlight Clinical
- Gwo xi Stem Cell
- GX Acquisition
- Qihan Biotech
- Hanyang University Medical Center
- HCW Biologics
- Hebei Yanda Ludaopei Hospital
- Help Therapeutics
- Henan Cancer Hospital
- Histocell
- Hope Biosciences
- Hospital Clinico Universitario de Valladolid
- Hospital del Rio Hortega
- Hospital for Special Surgery
- Hospital Infantil Universitario Nino Jesus
- Hospital San Carlos
- Hospital Vera Cruz
- Huashan Hospital
- Hyundai Bioland
- iCAR Bio Therapeutics
- iCell Gene Therapeutics
- ICON plc
- Infectious Disease Research Institute (IDRI)
- IMAC Regeneration Centers
- Immunitybio
- Implant Therapeutics
- Imugene
- IN8bio
- Incyte
- inno.N
- Innovate UK
- Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
- Institute of Hematology & Blood Diseases Hospital
- Instituto de Salud Carlos III
- International Research Institute Servier
- Janssen
- JCR Pharmaceutical
- jCyte
- Jiangsu Topcel-KH Pharmaceutical
- Jinling Hospital
- JW Therapeutics
- Kadimastem
- Kangstem Biotech
- Karolinska Institutet
- Kinesiometrics
- KSQ Therapeutics
- Kuur Therapeutics
- Kyocera
- Legend Biotech
- LG Chem
- Lineage Cell Therapeutics
- Link Health
- Longeveron
- Lonza
- LUMICKS
- Lung Biotechnology PBC
- M.D. Anderson Cancer Center
- Magellan Stem Cells
- Magenta Therapeutics
- Masonic Cancer Center
- MaxCyte
- Mayo Clinic
- McGill University Health Centre
- Medac
- Medeor Therapeutics
- Medical University of South Carolina
- MEDIPOST
- Medpace
- Medsenic
- Memorial Sloan Kettering Cancer Center
- Mendus
- Merck Sharp & Dohme
- Mercy Gilbert Medical Center
- Mesoblast
- Ministerio de Ciencia e Innovacion
- Ministry of Health & Welfare (MOHW)
- Nanfang Hospital of Southern Medical University
- Nanjing Bioheng Biotech
- Nanjing Enricnk Biotech
- NantKwest
- National Cancer Institute
- National Heart, Lung, and Blood Institute
- National Institute of Health Research and Development (NIHRD) (Indonesia)
- National University Hospital, Singapore
- Nature Cell
- Neurona Therapeutics
- NexImmune
- NextCell Pharma
- Nippon Shinyaku
- Nkarta Therapeutics
- Nohla Therapeutics
- Northern Therapeutics
- Novartis Pharmaceuticals
- NuVasive
- Ohio State University Comprehensive Cancer Center
- OmniaBio
- Oncternal Therapeutics
- Ono Pharmaceutical
- Orca Bio
- Orthofix
- Osiris Therapeutics
- Ossium Health
- Overland Pharmaceuticals
- Pandorum International
- PersonGen BioTherapeutics (Suzhou)
- Pfizer
- Pharmicell
- Phio Pharmaceuticals
- Pieris Pharmaceuticals
- Pierre Fabre
- Pluristem Therapeutics
- Poseida Therapeutics
- PPD
- Precision BioSciences
- Precision Biotech
- Pregene
- ProMab Biotechnologies
- Promethera Biosciences
- Protech Pharmaservices
- PT Prodia StemCell Indonesia (ProSTEM)
- Pulthera
- Q Therapeutics
- Quintiles
- R3 Stem Cell
- Red de Terapia Celular
- Regeneus
- ReNeuron
- Renji Hospital
- Renmin Hospital of Wuhan University
- Restem
- resTORbio
- RHEACELL
- Rigenerand
- Rigshospitalet
- Roche
- Royal Brompton and Harefield hospitals
- Ruijin Hospital
- S.Biomedics
- Salvat
- Sanofi
- Santen Pharmaceutical
- Sclnow Biotechnology
- SCM Lifescience
- Second Affiliated Hospital of Xi'an Jiaotong University
- Sentien Biotechnologies
- Seoul CRO
- Servier
- Shanghai Changzheng Hospital
- Shanghai East Hospital
- Shanghai GeneChem
- Shanghai General Hospital
- Shanghai iCELL Biotechnology
- Shanghai Jiao Tong University School of Medicine
- Shanghai Ninth People's Hospital
- Shanghai Public Health Clinical Center
- Shanghai Sixth People's Hospital
- Shenzhen Pregene Biopharma
- Shenzhen University General Hospital
- Shire
- SK Bioland
- SMT Bio
- Sorrento Therapeutics
- Springworks
- Staburo
- Stanford University
- Stemedica Cell Technologies
- Steminent Biotherapeutics
- Stempeutics Research
- Taiga Biotechnologies
- Taipei Veterans General Hospital
- Taiwan Bio Therapeutics
- Talaris Therapeutics
- Tang-Du Hospital
- TC BioPharm
- Teijin Pharma
- Tel Aviv Sourasky Medical Center
- Tessa Therapeutics
- Tevogen Bio
- The Affiliated Hospital of Guizhou Medical University
- The Affiliated Hospital of Xuzhou Medical University
- The Affiliated Union Hospital of Fujian Medical University
- The Cleveland Clinic
- The First Affiliated Hospital of Anhui Medical University
- The First Affiliated Hospital of Henan University of Science and Technology
- The First Affiliated Hospital of Kunming Medical College
- The First Affiliated Hospital of Soochow University
- The First Affiliated Hospital of University of Science and Technology of China
- The First Affiliated Hospital of Zhengzhou University
- The First People's Hospital of Hefei
- The Foundation for Orthopaedics and Regenerative Medicine
- The General Hospital of Western Theater Command
- The Marcus Foundation
- The Methodist Hospital Research Institute
- The Netherlands Organisation for Health Research and Development
- The Second Affiliated Hospital of Chongqing Medical University
- The Second Hospital of Shandong University
- The University of Texas Health Science Center
- The University of Texas MD Anderson Cancer Center
- Thomas Jefferson University
- TICEBA
- TiGenix (Acquired by Takeda)
- Timmune Biotech
- Tiziana Life Sciences
- Translational Biosciences
- Trinity College Dublin
- Tri-Service General Hospital
- Triumvira Immunologics
- Tscan Therapeutics
- Twist Bioscience
- UCI Medical Center
- UMC Utrecht
- UnicoCell Biomed
- Universitatsklinikum Hamburg-Eppendorf
- Universiti Kebangsaan Malaysia Medical Centre
- Universiti Tunku Abdul Rahman
- University Medical Center Groningen
- University of California
- University of Florida
- University of Kansas Medical Center
- University of Louisville
- University of Miami
- University of Minnesota
- University of Munich
- University of Sydney
- University of Valladolid
- University of Wisconsin-Madison
- Uppsala University
- National Cancer Institute
- Utooth Biological Technology
- VetStem Biopharma
- ViaCyte
- ViGenCell
- Vinmec Research Institute of Stem Cell and Gene Technology
- Vinnova
- Virginia Contract Research Organization
- Viscofan
- Vitro Biopharma
- Washington University
- Wugen
- Wuhan Jinyintan Hospital
- Xindu (A subsidiary of Xintela)
- Xinqiao Hospital of Chongqing
- Xintela
- Xuzhou Medical University
- Zelluna Immunotherapy
- Zhejiang University
- Zhengzhou University
For more information about this report visit https://www.researchandmarkets.com/r/bbftbp
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
